Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

UF researchers report: Immunosuppressant drug prevents late rejection of transplanted kidneys

23.01.2003


UF researchers report: Immunosuppressant drug prevents late rejection of transplanted kidneys



A drug that suppresses the immune system and prolongs the survival of donated kidneys in patients in the first months after transplantation also has the ability to block organ rejection over the long haul, University of Florida researchers have found.

The drug, mycophenolate mofetil, has been shown to decrease acute rejection by 50 percent compared with an older agent commonly used, azathioprine, also known as Imuran. In addition, the relative newcomer has been associated with longer kidney survival compared with azathioprine.


Previous research indicated that in some cases patients could eventually stop taking mycophenolate mofetil, which goes by the trade name CellCept, particularly because most episodes of rejection occur within the year after transplantation. That has left physicians who care for kidney transplant patients with many questions, said Dr. Bruce Kaplan, a professor of medicine, and of pharmacology and therapeutics at UF’s College of Medicine.

The UF study, published in this month’s issue of the American Journal of Transplantation, also has prompted new theories about the physiologic processes that lead to the severe scarring of the kidney that doctors call chronic rejection, which can cause the organ to malfunction or even fail. The UF findings suggest that some chronic rejection actually may be the culmination of a series of episodes of acute rejection, an abrupt immunologic attack on the donated kidney led by a vanguard of immune cells bent on destroying it. Acute rejection often can be reversed by medicines that temper this assault.

"Chronic rejection, next to the patient dying, is the most common reason patients lose their transplanted kidney," said Kaplan, also medical director of the kidney and pancreas transplant program at the UF Shands Transplant Center. "Physicians have yet to pinpoint its precise cause, and there is no known treatment for this type of injury. Acute rejection appears to be linked to that. People with acute rejection have a higher risk of developing this process.

"We believe that part of the link is people who develop acute rejection are more at risk of a later rejection, and it’s caused by the cumulative damage that’s occurring as opposed to something magical that happens with just one acute rejection episode," he said. About 50,000 patients await kidney transplantation--a number expected to double by 2010, according to the United Network for Organ Sharing. Yet the availability of donor kidneys is strikingly low. Each year, only 10,000 kidney transplants are performed in the United States. Although remarkable advances in organ transplantation have made headlines in recent decades, preventing the body from recognizing a transplanted organ as foreign has impeded long-term survival for many patients.

"One of the big questions has been how long you should stay on this drug CellCept," Kaplan said. "What does this drug, if you stay on it for a year, two years or three years, do to rejections that happen late? Everybody used to say rejection occurs within the first six months and if it doesn’t, it won’t happen later. But we found that acute rejection can actually happen two or three years down the line."

Kaplan, together with Dr. Herwig-Ulf Meier-Kriesche, an associate professor of medicine at UF and clinical director of renal transplant at Shands at UF medical center, worked with colleagues at the University of Pennsylvania Cancer Center to analyze U.S. Renal Data System data from nearly 48,000 patients who received a single kidney transplant between 1988 and 1998. The study was funded in part by a grant from Roche Laboratories, which manufactures CellCept.

Researchers compared patients who continuously took mycophenolate mofetil or the traditional drug, azathioprine, for a year to see whether either therapy lowered the incidence of late acute rejection, defined as rejection occurring beyond the first year after transplantation. They also assessed how patients who took either drug for two years fared.

Compared with azathioprine, mycophenolate mofetil was associated with up to a 72 percent decreased risk of developing late acute rejection. In addition, the incidence of acute rejection episodes two and three years post-transplantation was significantly lower in patients on mycophenolate mofetil.

"CellCept blocks rejection in the first year--halves it over the old drug--and virtually eliminates rejection in the second and third year if you stay on it, even if you’ve had a rejection in the first year," Kaplan said. "But if you had an episode of rejection in the first year and you are on the older therapy, your rejection rate in the second year is about 10 percent. That would indicate these patients are at high risk, and the older drug is not protecting them from late rejection, which often goes unchecked because by that time they are seeing physicians in the community and they may not be tracked as often. This wasn’t really appreciated before."

The occurrence of acute rejection may actually signal a patient’s likelihood of developing rejection a year or more after transplantation, and a therapy that prevents rejection early may be a marker for a therapy that prevents rejection later, Kaplan added. Physicians likely will track transplant patients much more closely over the long term, he said, adding that further study is needed to determine the optimal duration of treatment with mycophenolate mofetil.

"It may make people hesitant to stop the drug," Kaplan said. "More importantly, it may change the way people think about lowering doses."

In recent years, several newer agents have been shown to reduce the early acute rejection rate better than traditional medications, but it has been harder to demonstrate they have a long-term positive effect, as would be expected, said Dr. J. Harold Helderman, medical director of the Vanderbilt University Transplant Center.

"(With CellCept) the effect toward increased long-term organ survival was greater than predicted by merely reducing acute rejection early and thus potentially is an issue of the specific molecule used," he said. "The transplant community has been struggling with how long to use these new and more expensive immunosuppressant medications like CellCept. The newer work demonstrating the importance of low-level but persistent risk for acute rejection and its inhibition by CellCept is additional evidence for the strong recommendation that this particular medication be continued when tolerated by patients."

Melanie Fridl Ross | EurekAlert!
Further information:
http://www.ufl.edu/

More articles from Health and Medicine:

nachricht Millions through license revenues
27.04.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New High-Performance Center Translational Medical Engineering
26.04.2017 | Fraunhofer ITEM

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Making lightweight construction suitable for series production

More and more automobile companies are focusing on body parts made of carbon fiber reinforced plastics (CFRP). However, manufacturing and repair costs must be further reduced in order to make CFRP more economical in use. Together with the Volkswagen AG and five other partners in the project HolQueSt 3D, the Laser Zentrum Hannover e.V. (LZH) has developed laser processes for the automatic trimming, drilling and repair of three-dimensional components.

Automated manufacturing processes are the basis for ultimately establishing the series production of CFRP components. In the project HolQueSt 3D, the LZH has...

Im Focus: Wonder material? Novel nanotube structure strengthens thin films for flexible electronics

Reflecting the structure of composites found in nature and the ancient world, researchers at the University of Illinois at Urbana-Champaign have synthesized thin carbon nanotube (CNT) textiles that exhibit both high electrical conductivity and a level of toughness that is about fifty times higher than copper films, currently used in electronics.

"The structural robustness of thin metal films has significant importance for the reliable operation of smart skin and flexible electronics including...

Im Focus: Deep inside Galaxy M87

The nearby, giant radio galaxy M87 hosts a supermassive black hole (BH) and is well-known for its bright jet dominating the spectrum over ten orders of magnitude in frequency. Due to its proximity, jet prominence, and the large black hole mass, M87 is the best laboratory for investigating the formation, acceleration, and collimation of relativistic jets. A research team led by Silke Britzen from the Max Planck Institute for Radio Astronomy in Bonn, Germany, has found strong indication for turbulent processes connecting the accretion disk and the jet of that galaxy providing insights into the longstanding problem of the origin of astrophysical jets.

Supermassive black holes form some of the most enigmatic phenomena in astrophysics. Their enormous energy output is supposed to be generated by the...

Im Focus: A Quantum Low Pass for Photons

Physicists in Garching observe novel quantum effect that limits the number of emitted photons.

The probability to find a certain number of photons inside a laser pulse usually corresponds to a classical distribution of independent events, the so-called...

Im Focus: Microprocessors based on a layer of just three atoms

Microprocessors based on atomically thin materials hold the promise of the evolution of traditional processors as well as new applications in the field of flexible electronics. Now, a TU Wien research team led by Thomas Müller has made a breakthrough in this field as part of an ongoing research project.

Two-dimensional materials, or 2D materials for short, are extremely versatile, although – or often more precisely because – they are made up of just one or a...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Expert meeting “Health Business Connect” will connect international medical technology companies

20.04.2017 | Event News

Wenn der Computer das Gehirn austrickst

18.04.2017 | Event News

7th International Conference on Crystalline Silicon Photovoltaics in Freiburg on April 3-5, 2017

03.04.2017 | Event News

 
Latest News

Bare bones: Making bones transparent

27.04.2017 | Life Sciences

Study offers new theoretical approach to describing non-equilibrium phase transitions

27.04.2017 | Physics and Astronomy

From volcano's slope, NASA instrument looks sky high and to the future

27.04.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>